Published in Cardiovasc Drugs Ther on January 01, 2005
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men | NCT00256256
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev (2007) 2.14
Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts. Stem Cells Transl Med (2012) 1.54
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol (2009) 1.41
PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol (2007) 1.39
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab (2009) 1.38
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol (2011) 1.19
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol (2011) 1.14
Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol (2013) 0.99
Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One (2011) 0.95
Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol (2011) 0.94
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol (2013) 0.91
Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3. Cardiovasc Diabetol (2014) 0.89
Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One (2011) 0.89
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. Saudi J Gastroenterol (2010) 0.87
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord (2009) 0.87
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol (2016) 0.87
Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Exp Biol Med (Maywood) (2012) 0.83
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease. Diabetes Care (2012) 0.82
Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther (2010) 0.81
Impact of hypoglycemic agents on myocardial ischemic preconditioning. World J Diabetes (2014) 0.79
Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy. Cardiovasc Endocrinol (2012) 0.79
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol (2015) 0.78
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart (2015) 0.78
Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart (2015) 0.77
Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart. PLoS One (2015) 0.77
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation (2010) 3.72
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 3.63
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med (2015) 3.60
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation (2007) 2.75
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther (2007) 2.50
Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res (2008) 2.37
Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res (2006) 2.30
Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res (2004) 2.25
Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res (2003) 2.25
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2010) 2.20
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol (2004) 2.18
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev (2007) 2.14
Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res (2007) 2.01
The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med (2005) 1.88
Remote ischaemic preconditioning involves signalling through the SDF-1α/CXCR4 signalling axis. Basic Res Cardiol (2013) 1.88
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab (2002) 1.83
Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology (2006) 1.80
Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab (2004) 1.80
Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol (2011) 1.74
Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis (2008) 1.74
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2013) 1.72
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol (2005) 1.71
Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.69
Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis (2010) 1.68
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol (2003) 1.68
The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol (2009) 1.66
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J (2013) 1.65
Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes (2005) 1.62
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart (2011) 1.55
Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol (2005) 1.54
The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol (2011) 1.53
'Conditioning' the heart during surgery. Eur J Cardiothorac Surg (2009) 1.51
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res (2004) 1.46
Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther (2007) 1.45
The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol (2003) 1.44
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res (2008) 1.44
Is this truly ischemic preconditioning? Circ Res (2006) 1.41
The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol (2010) 1.40
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol (2007) 1.38
Premature meta-analysis of remote ischemic preconditioning. Am J Cardiol (2009) 1.38
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol (2010) 1.37
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol (2006) 1.34
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 1.33
Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther (2009) 1.27
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol (2007) 1.27
Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J (2010) 1.26
Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol (2003) 1.23
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol (2003) 1.23
Public health informatics training in New Mexico. J Med Libr Assoc (2007) 1.22
The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med (2008) 1.21
Time to take myocardial reperfusion injury seriously. N Engl J Med (2008) 1.20
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19
Hypoxic regulation of hand1 controls the fetal-neonatal switch in cardiac metabolism. PLoS Biol (2013) 1.18
Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech (2010) 1.18
Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol (2005) 1.18
Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res (2002) 1.17
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol (2011) 1.17
Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal (2010) 1.17
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther (2007) 1.16
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci (2008) 1.15
PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol (2002) 1.14
p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning. FEBS Lett (2003) 1.14
Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res (2011) 1.13
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol (2009) 1.13
The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther (2010) 1.12
Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol (2011) 1.08
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Göttingen minipigs in vivo. Am J Physiol Endocrinol Metab (2005) 1.07
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol (2002) 1.07
Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther (2010) 1.07
Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation (2006) 1.06
Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther (2013) 1.06
Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol (2004) 1.06
Cardioprotective growth factors. Cardiovasc Res (2009) 1.05
Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab (2002) 1.04